Gene · 7150
Papers4,103
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 4,103
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage. | Br J Cancer | 2026 | 41986659 | PubTator, text mining | PubMed |
| Slx4 and Fun30/SMARCAD1 coordinate S-phase checkpoint regulation and replication fork protection in response to Top1-DNA crosslinks. | Nucleic Acids Res | 2026 | 41978269 | PubTator, text mining | PubMed |
| Topoisomerase 1-DNA complexes are preferentially recognised by a subset of anti-topoisomerase 1 autoantibodies and their corresponding B cell receptors in systemic sclerosis. | Ann Rheum Dis | 2026 | 41968004 | PubTator, text mining | PubMed |
| TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer. | J Immunother Cancer | 2026 | 41932810 | PubTator, text mining | PubMed |
| R-loop disruption triggers irreversible topoisomerase 1-DNA cleavage complex formation during AID-dependent IgH gene diversification. | Proc Natl Acad Sci U S A | 2026 | 41931514 | PubTator, text mining | PubMed |
| Ferroptosis as a Translational Axis in Small Cell Lung Cancer: A Systematic Review of Redox Pathways and Precision Oncology Prospects. | Oncol Res | 2026 | 41930142 | PubTator, text mining | PubMed |
| Synthesis and biological evaluation of novel fused pyridopyrimidine derivatives as topoisomerase I inhibitors and as potential antitumor agents: promising results in lung, ovary and gastric cancer. | Eur J Med Chem | 2026 | 41922123 | PubTator, text mining | PubMed |
| Calibrating deep classifiers with dynamic confidence propagation and adaptive normalization. | Sci Rep | 2026 | 41917068 | PubTator, text mining | PubMed |
| CancerHubs Data Explorer: a web application for investigating mutation-enriched protein interaction hubs in human cancers. | BioData Min | 2026 | 41913220 | PubTator, text mining | PubMed |
| Sequential pattern transformer (SPT): a generative and interpretable framework for predicting disease trajectories. | Neural Comput Appl | 2026 | 41907562 | PubTator, text mining | PubMed |
| Low-data cross-modal adaptation for remote sensing with proxy-enhanced multi-granularity feature caching. | Sci Rep | 2026 | 41896599 | PubTator, text mining | PubMed |
| Decoding TCR recognition via geometric deep learning of immunological fingerprints. | Brief Bioinform | 2026 | 41834397 | PubTator, text mining | PubMed |
| CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress. | Cancers (Basel) | 2026 | 41827815 | PubTator, text mining | PubMed |
| KAT2B-mediated epigenetic suppression of RAD51C enhances olaparib sensitivity in colorectal cancer. | Cancer Chemother Pharmacol | 2026 | 41826541 | PubTator, text mining | PubMed |
| Synthesis, Biological Evaluation, and Theoretical Study of Indenoquinolinylphosphine Oxide Derivatives as Topoisomerase 1 Inhibitors and Antiproliferative Agents. | ChemMedChem | 2026 | 41824931 | PubTator, text mining | PubMed |
| Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy. | Clin Transl Med | 2026 | 41804750 | PubTator, text mining | PubMed |
| Dual targeting of topoisomerase I and DNA G-quadruplexes enhances senescence and chemosensitivity in colorectal cancer. | Commun Biol | 2026 | 41803560 | PubTator, text mining | PubMed |
| Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy. | Oncol Res | 2026 | 41799521 | PubTator, text mining | PubMed |
| Prognostic Significance of DNA Repair Gene mRNA Expression in Early-Stage Breast Cancer: Insights into Clinical Relevance. | Oncol Res | 2026 | 41799499 | PubTator, text mining | PubMed |
| Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody-drug conjugates in breast cancer. | Breast | 2026 | 41785741 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7150/papers?page=4